(E)-diphenyldiazene-4,4'-dicarbaldehyde | 140661-40-1

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: (E)-diphenyldiazene-4,4'-dicarbaldehyde
• 英文别名: (E)-4,4′-(diazene-1,2-diyl)dibenzaldehyde；trans-4,4'-(diazene-1,2-diyl)dibenzaldehyde；(E)-4,4'-(diazene-1,2-diyl)dibenzaldehyde；4,4'-diformylazobenzene；4,4'-azobenzaldehyde；4,4'-Azobenzaldehyd
• CAS: 140661-40-1
• 化学式: C₁₄H₁₀N₂O₂
• 分子量: 238.246
• InChiKey: QRHDFPNRGBRHTC-FOCLMDBBSA-N

物化性质

• 熔点：
  238 °C(Solv: chloroform (67-66-3))
• 沸点：
  449.9±30.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  18.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.86
• 氢给体数：
  0.0
• 氢受体数：
  4.0

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  (E)-diphenyldiazene-4,4'-dicarbaldehyde 在 哌啶 作用下， 以 aq. phosphate buffer 、 乙腈 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  使用可逆共价键用偶氮苯交联剂修饰蛋白质

  摘要：

  设计用于蛋白质化学修饰的硫醇反应试剂一般不能直接用于细胞内靶标的修饰，因为细胞内存在毫摩尔浓度的谷胱甘肽有效地胜过与目标硫醇的反应。在这里，我们报告了使用具有两个反应位点的基于氰基丙烯酸酯的硫醇反应性交联剂 ( BCNA ) 实现目标选择性的平衡熵策略。该化合物与含有适当间隔的硫醇对的目标肽和蛋白质反应时表现出 ≳200 倍的选择性，而与单硫醇反应。交联剂偶氮苯部分的光异构化可用于影响目标肽或蛋白质的构象。这种方法提出了细胞内肽和蛋白质靶标化学修饰的一般策略。

  DOI：

  10.1039/d2ob01656g
• 作为产物：
  描述：

  bis (4-[1,3]-dioxolan-2-yl-phenyl) diazine 在 硫酸 作用下， 以 甲醇 、 水 为溶剂， 生成 (E)-diphenyldiazene-4,4'-dicarbaldehyde
  参考文献：
  名称：

  Cage structure helps to improve the photoisomerization efficiency of azobenzene

  摘要：

  Azobenzene (Azo) usually cannot achieve relatively high photoisomerization efficiency because of the overlap of the n-pi* absorption bands between their isomers. In this work, three Azo units were integrated into a cage (AC) and adopt a nonplanar configuration. The distortion of the Azo units in AC results in the reduction of the n-pi* band overlap, and consequently increases the full E -> Z and Z -> E photo-conversions to 87% and 85%, respectively, which are even higher than those of the planar parent azobenzene ADA (85% of E -> Z and 76% of Z -> E). Further theoretical calculations demonstrate that the n-pi* excitation energy gap between the two AC isomers is larger than that of ADA, which further supports the reduction of the n-pi* overlap. This AC shows the highest E <-> Z photoisomerization efficiency among the symmetrical organic covalent cages yet reported. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2020.152626

文献信息

• [EN] ENCAPSULATES<br/>[FR] PRODUITS ENCAPSULÉS
  申请人：PROCTER & GAMBLE

  公开号：WO2013022949A1

  公开（公告）日：2013-02-14

  The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

  本申请涉及封装体、组合物、包含这种封装体的产品，以及制备和使用这种封装体的方法。这种封装体包括一个包含香水的核心和封装该核心的壳，这种封装体可以选择性地包含一个参数平衡剂，该壳包括一个或多个偶氮苯基团。
• Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
  申请人：Hikma Pharmaceuticals Co. Ltd.

  公开号：EP1688413A1

  公开（公告）日：2006-08-09

  The present invention relates to novel compounds for the prophylaxis and treatment of inflammatory bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of agents that are active by themselves or can deliver tin the large intestine active forms of the drugs such as 5ASA or benzoxazole acetic acid or platelet activating factors. The mechanism of the release is based on bacterial cleavage of an azo linkage in the mammalian lower bowel to release the active compound(s).

  本发明涉及通过给予有效剂量的新化合物进行预防和治疗炎症性肠病（IBD），这些化合物以适当的药物剂量给药，这些化合物本身具有活性或者可以在大肠中释放药物的活性形式，如5-氨基水杨酸（5ASA）或苯并噁唑乙酸或血小板活化因子。释放机制基于细菌在哺乳动物下肠中裂解偶氮键来释放活性化合物。
• Novel compounds for the prophylaxis and treatment of inflammatory bowel diseases
  申请人：Jilani Jamal

  公开号：US20070043003A1

  公开（公告）日：2007-02-22

  Novel compounds are disclosed for the prophylaxis and treatment of inflammatory bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of agents that are active by themselves or can deliver tin the large intestine active forms of the drugs such as 5ASA or benzoxazole acetic acid or platelet activating factors. The mechanism of the release is based on bacterial cleavage of an azo linkage in the mammalian lower bowel to release the active compound(s).

  揭示了用于预防和治疗炎症性肠病（IBD）的新化合物，通过在适当的药物剂量中给予能够自身活跃或能够在大肠中释放药物的活性形式的药剂，如5-氨基水杨酸（5ASA）或苯并噁唑乙酸或血小板活化因子。释放机制基于细菌在哺乳动物下肠中裂解偶氮键以释放活性化合物。
• One-pot synthesis of terpyridines and macrocyclization to <i>C</i>₃-symmetric cyclosexipyridines
  作者：Lucie Masciello、Pierre G Potvin

  DOI：10.1139/v03-020

  日期：2003.3.1

  Four examples of 2,6-dicinnamoylpyridines were obtained in 60–65% yields in condensations of commercially available 2,6-diacetylpyridine and benzaldehydes in 1:2 stoichiometry. At 2:1 ratios, four related 6,6''-diacetylated-4'-arylterpyridines were isolated in 70–73% yields in one-pot condensations in the presence of NH₃. 4,4'-Azo benzaldehyde, prepared from nitrobenzaldehyde in three steps and 40% overall yield was similarly converted to a novel azo-linked bis(terpyridine) in 50% yield in a reaction that assembles seven molecules in one step. The 6,6''-diacetylated-4'-arylterpyridines and the correspondingly substituted 2,6-dicinnamoylpyridines were condensed in 1:1 ratio together with NH₃ to form 4,4'',4^IV-triarylcyclosexipyridines in 22–26% yields. These were obtained as mixed Na⁺ and K⁺ complexes and were insoluble amorphous solids, except for one example bearing 4-neopentoxyphenyl substituents. ¹H NMR showed that the 4,4'',4^IV-tri(4-neopentoxyphenyl)cyclosexipyridine complexes form aggregates in solution and at low concentrations show twofold symmetry arising from a loss of planarity.Key words: terpyridines, 4'-aryl-6,6''-diacetylterpyridines, azo-bisterpyridine, cyclosexipyridines, macrocyclization.

  2,6-二肉桂酰基吡啶的四个例子在商业可获得的2,6-二乙酰基吡啶和苯甲醛的1:2化学计量比下以60-65%的产率得到。在2:1的比例下，在NH₃存在下，通过一锅法合成了四个相关的6,6''-二乙酰化-4'-芳基三吡啶，产率为70-73%。从硝基苯甲醛经过三步反应制备的4,4'-偶氮苯甲醛，总产率为40%，类似地转化为一种新型偶氮连接的双(三吡啶)产率为50%，在一步反应中组装了七个分子。6,6''-二乙酰化-4'-芳基三吡啶和相应取代的2,6-二肉桂酰基吡啶以1:1的比例与NH₃一起缩合，形成了22-26%的4,4'',4^IV-三芳基环六吡啶。这些产物以混合的Na⁺和K⁺络合物的形式获得，是不溶的非晶固体，除了一个带有4-新戊氧基苯基取代基的例子。¹H NMR显示，4,4'',4^IV-三(4-新戊氧基苯基)环六吡啶络合物在溶液中形成聚集体，在低浓度下显示出双轴对称性，这是由于失去平面性所致。关键词：三吡啶，4'-芳基-6,6''-二乙酰三吡啶，偶氮双三吡啶，环六吡啶，大环化合物。
• Preparation and Structures of New Azobenzene Derivatives with a 3-Guaiazulenylvinyl Group
  作者：Shin-ichi Takekuma、Kenji Fukuda、Toshie Minematsu、Hideko Takekuma

  DOI：10.1246/bcsj.82.1398

  日期：2009.11.15

  henyl}(3-guaiazulenyl)methylium ion compounds are reported. Similarly, Wittig reaction of (E)-diphenyldiazene-4,4'-dicarbaldehyde with the same reagent under the same reaction conditions as the above affords only E forms (E)-4-(E)-4-[2-(3-guaiazulenyl)vinyl]phenyldiazenyl}benzaldehyde and (E)-bis(E)-4-[2-(3-guaiazulenyl)vinyl]phenyl)diazene in 7 and 24% yields. Furthermore, reaction of guaiazulene

  (E)-4-(4-甲氧基苯基二氮烯基)苯甲醛和(E)-4-[4-(二甲氨基)苯基二氮烯基]-苯甲醛与(3-愈创甘油基甲基)三苯基溴化鏻在乙醇中在乙醇钠存在下于25℃的Wittig反应°C 在氩气下保持 24 小时仅产生 E 形式 (E)-4- (E)-4-[2-(3-guaiazulenyl)vinyl] 苯基二氮烯基}甲氧基苯和 (E)-N,N-二甲基-4- (E)-4-[2-(3-愈创甘油基)乙烯基]苯基二氮烯基}苯胺的产率为71%和73%。两种新的扩展 π 电子系统与结构相关（和离域）π 电子系统（3-愈创甘油基）[（E）-4-（4-甲氧基苯基二氮烯基）苯基]甲基鎓的光谱性质和晶体结构的比较研究离子和(E)-4-[4-(二甲氨基)苯基二氮烯基]苯基}(3-愈创甘油基)甲基鎓离子化合物被报道。同样， (E)-diphenyldiazene-4,4' 的 Wittig 反应 -二甲